Simplifying Progress



Investor Presentation

September 2025

Agenda

Overview | Strategy

Bioprocess Solutions Division (BPS)

Lab Products & Services Division (LPS)

H1 2025 Results | FY 2025 Guidance

Partner of life science research and the biopharmaceutical industry

Good health and well-being at the focus of Sartorius' business activities

Our mission

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.

Sartorius at a glance

~€3.4bn
Sales revenue

~14%
Sales CAGR 2014-2024

28.0%
EBITDA margin[1]

~75%
Recurring revenues

~13,500
Employees

Two divisions focused on attractive biopharma and life science markets

80%
Bioprocess Solutions
Division

20%
Lab Products & Services
Division

~85%
with life science customers

FY 2024 figures, 1 ul. EBITDA margin excluding extraordinary items

Track record of profitable sales growth above market

Sales revenue; EBITDA margin[1]



1 ul. EBITDA margin excluding extraordinary items

Proven growth strategy driving share gains

- Increase share of wallet by addressing critical steps at customers
- Strong focus on recurring revenue
- Solution offering capitalizes on cross-divisional synergies and internal application know-how
- Innovations mainly through M&A and cooperations; technological integration via strong inhouse R&D

SARTORIUS

Simplifying progress: Enabling the discovery and production of biopharmaceuticals



Attractive market environment offers strong growth opportunities

Growing and aging population

>9.5 billion people by 2050[1]

World population over age 65 in 2050
~1.6bn



World population over 65 in 2024
~0.8bn

Biologics are gaining importance[2]

Sales share of biologics in 2028
~45%



Sales share of biologics in 2024
~41%

~10% CAGR[3]
biopharma market
2024 – 2028

1 United Nations: World Population Prospects, 2024 2 Evaluate Pharma: World Preview 2024, August 2024 3 Company estimates based on industry reports (e.g. IQVIA, Evaluate Pharma, GlobalData) 2024

SARTORIUS

Addressing customer needs across all types of biopharma drugs

1796	1818	1982	1986	2012 / 2017	2020	2023
Vaccines	Blood products	Recombinant proteins	Monoclonal antibodies	Cell & gene therapies	mRNA vaccines	CRISPR gene therapy

Established Biopharmaceuticals

- Largely mature modalities with standardized processes
- Increasing competition through biosimilars
- Novel, complex antibody derivates continue to drive innovation

Costs, efficiency, acceleration, automation

Next Generation

- Small but fast-growing market
- Immature processes leading to very high costs of therapies

Yields, robustness and scalability

Customer needs

SARTORIUS

Cell and gene therapies (CGT): An increasingly relevant market segment

~30% of biopharma pipeline is focusing on CGT[1]

~70%
Other biologics

~30%
CGT

- >8,000 CGT candidates in development[1]
- 9 new CGT (2023: 7) approvals in 2024 out of 47 BLA approvals in total (2023: 41)[2]

Number of commercial processes is expanding rapidly

~70
approved CGT globally[1]

23
CGT approvals 2022-2024

10-20
CGT approvals expected p.a. by 2025[2]

1 GlobalData, January 2025 2 FDA, includes CDER and CBER approvals

SARTORIUS

Extensive technology platform for cell and gene therapy applications

Biological Industries

Cell culture media

CellGenix

Growth factors and cytokines

Xell

Media and supplements

Albumedix

Recombinant Albumin

Polyplus

Transfection reagents and plasmid DNA

+

Up & downstream solutions

+

Cell line development, plasmid design & manufacturing and testing services

Sartorius CGT exposure >10% of BPS sales revenue

Integration of innovative technologies is a Sartorius core competency

Acquisitions
of complementary technologies

- Media & reagents
- Chromatography
- Bioanalytical instruments

Cooperations
with partners leading in their fields

- Process intensification
- Bioprinting
- Artificial intelligence
- Cell models

Own Product Development
in areas of core competencies

- Separation
- Cell cultivation technologies
- Lab analysis
- Automation

SARTORIUS

Proven M&A approach, recent focus on three strategic key areas

Build-up of BioAnalytics portfolio

Intellicyt (2016)

Essen BioScience (2017)

Octet business from Danaher (2020)

ALS Automated Lab Solutions (2022)

MATTEK A BICO COMPANY

Mattek (2025)

Unique portfolio for Advanced Therapies

Biological Industries (2019)

BIA Separations (2020)

CellGenix (2021)

Xell (2021)

Albumedix (2022)

Polyplus (2023)

Intensified technologies for downstream processing

WaterSep (2020)

Danaher chromatography (2020)

BIA Separations (2020)

Novasep chromatography (2022)

Acquisition of MatTek to add innovative advanced cell model technology to the LPS portfolio

Ashland, Mass., US (headquarters); Bratislava, Slovakia

>80 employees

Revenue of > USD 20m in 2024; margins similar to LPS division



3D in vitro microtissue models

Strategic rationale

- A leading provider of human cell-based microtissues and 3D models for in vitro testing to accelerate preclinical drug development processes and reduce / replace animal testing
- Strengthens Sartorius' cell technology portfolio by advanced cell models, which provide more relevant, cost-efficient and reproducible results
- Synergistic to LPS' existing cell analysis instruments, reagents, and AI models

Acquisition terms

- Purchase price of USD ~80m (€ ~72m) in cash
- Acquisition closed as of July 1, 2025

SARTORIUS

Resilient global setup, well prepared for further growth

- Global resilience
- Redundant capacities
- Operational excellence
- Customer proximity

Capex
in millions of €;
ratio in %



Capex composition

Major projects	~X%
Regular expansion	~3%
Capitalized R&D	~2%
Maintenance	~3%

cell culture components

clean rooms, product development, labs

media, bags, filtration, labs, training

Investments 2025, select projects

SARTORIUS

Ambitious sustainability agenda in implementation

2030 mid-term ambitions

~10%
av. reduction of CO_2eq emission intensity p.a. (Scopes 1-3)

Zero
avoidable[1] emissions in Scopes 1 and 2

100%
electricity from renewable sources

2045 long-term ambition

Net-zero emissions

Decarbonization of the entire supply chain in collaboration with suppliers and customers

1 Process emissions from membrane manufacturing are currently considered unavoidable based on available technology

Midterm outlook to 2028: Expect to continue outgrowing the market

	BPS	LPS	Sartorius Group
Sales revenue CAGR to 2028	Low to mid-teens %	Mid to high single-digit %	Low-teens %
Underlying EBITDA margin in 2028	~36%	~28%	~34%

- ~1/5 of sales revenue growth to come from acquisitions in both divisions and the Group
- Margin targets include expenses for reduction of the company's CO_2 emission intensity of around 1% of sales

Midterm targets based on current currency exchange rates; underlying EBITDA excluding extraordinary items

Agenda

Overview | Strategy

Bioprocess Solutions Division (BPS)

Lab Products & Services Division (LPS)

H1 2025 Results | FY 2025 Guidance

BPS: Solution provider for biomanufacturing

~€2.7bn
Sales revenue

29.3%
EBITDA margin[1]

~80%
Recurring revenues

~90%
Sales share biopharma



Filtration & Purification

Fluid management

Fermentation

Cell culture media

FY 2024 figures, 1 ul. EBITDA margin excluding extraordinary items

Track record of dynamic growth

BPS sales revenue; EBITDA margin[1]



Pillars of growth CAGRs 2022–2027[2]

Pharma market	→	~3-6%
Biopharma market	→	~10%
Biosimilars	→	~15%
CGT	→	~20%
Single-use	→	~15%

1 ul. EBITDA margin excluding extraordinary items 2 IQVIA 2024, Global Data 2024, Roots Analysis 2021, Markets & Markets 2024

Covering most steps of the biopharmaceutical manufacturing process

- Differentiated by the range and completeness of the portfolio
- Excellent positioning in key single-use technologies
- Internationally recognized supplier enabling innovation in bioprocessing through own R&D and partnerships



Generating revenue throughout the lifecycle of a biopharma drug

Products specified into customers' validated processes; recurring revenues with consumables after approval of the drug by health authorities (e.g. FDA, EMA)

Stage	Pre-clinical →	Clinical →	Commercial
Business stickiness	●	●●	●●●
Volume			
% Revenue	~10%	~30%	~60%

Attractive business model

Recurring revenue

~80%

- Razor/razor blade
- Spec`d in

Competitive product offering



Pie charts indicate completeness of product offering

Biosimilars: Strong growth, big opportunities

- Major blockbuster biologics are going off-patent
- Time-to-market is key as only the first providers are most likely profitable
- Several approvals in Asia and Europe; U.S. at the beginning
- For now, relatively small market but with strong growth
- Single-use is the preferred platform for biosimilars

Biosimilars will outperform the biologics market[1]



Growing number of approved biosimilars[2]

E.U. and U.S.



1 Source: MarketsandMarkets, 2024; EvaluatePharma, 2024 2 FDA and EMA

Pioneer and leader in the growing single-use technology market

Single-use market penetration expected to increase from ~35% to ~75%

Single-use products offer advantages over conventional stainless-steel devices

- Capex|Opex reduction over entire lifecycle
- Reduced risk of cross-contamination
- Higher flexibility; advantageous for biosimilars



Source: Andrew Sinclair et al., 2008; Sartorius

Single-use allows manufacturers to mitigate investment risks

- Construction of stainless-steel based facilities takes longer and is more complex compared to single-use
- Therefore, investment in stainless-steel facilities has to start in early clinical phase II
- The construction of single-use facilities may start in clinical phase III, reducing investment risks of clients

	Clinical Phase I	Clinical Phase II	Clinical Phase III
Probability that candidate advances to next stage	~ 60%	~ 30%	~ 50%
Probability of approval	~ 10%	~ 15 %	~ 50%

Data based on: Wong et al., 2018

Leveraging digital tools for faster process development and cost-efficient bioprocessing



Combination of bioprocess sensors, analyzers and software to…

…collect, monitor and control quality-critical parameters

…analyze data to obtain a better process understanding

…use knowledge for process development, optimization and automation

Vision: Digital end-to-end biopharma process development & manufacturing

Expected **high impact** of AI, in-silico simulations, predictive models, and automation

Sartorius **well-positioned** to bring benefits to customers

Faster results	New insights
More throughput	Reduced risk
Higher flexibility	Lower costs

Limited dependence on individual accounts

Long-term business relationships with leading global (bio-) pharma companies

Limited dependence on individual accounts

Sales to Top 50 customers
in 2024, € in millions



- More than half of 2024 BPS sales were generated with the Top 50 customers
- No individual customer accounts for more than 5% of BPS sales revenue

High innovation dynamics in biopharma

Development of new drugs and vaccines must be accelerated, e.g. through more automation

Increased efficiency possible in the production of 'classic' biopharmaceuticals and biosimilars

New tools and methods required e.g. for novel cell and gene therapies

Future drug manufacturing is more automated, intensified and scalable

Agenda

Overview | Strategy

Bioprocess Solutions Division (BPS)

Lab Products & Services Division (LPS)

H1 2025 Results | FY 2025 Guidance

LPS: Premium supplier for life science research and quality control labs

~€691mn
Sales revenue

22.9%
EBITDA margin[1]

50%
Recurring revenue

~60%
Sales share Life Sciences

Portfolio includes lab instruments, consumables, software and services

Bioanalytics

Lab instruments

Lab consumables

FY 2024 figures, 1 ul. EBITDA margin excluding extraordinary items

Continuous transition to a higher growth and profitability profile

LPS sales revenue; EBITDA margin[1]



Growth drivers

- Sales & Marketing pivot to attractive segments and regions
- Attractive portfolio mix coupled with M&A
- Launch of innovative products
- Improved brand awareness

Overall addressable market growing in the mid- to high- single digits over the long-term

1 ul. EBITDA margin excluding extraordinary items

Focus on attractive life science market; regional profile increasingly balanced

Sales revenue share by segment, 2024 vs. 2018



Sales revenue share by geography, 2024 vs. 2018



R&D efficiency key value lever for biopharma customers

Biopharma R&D needs to innovate

$161bn R&D expenditure of large pharma customers in 2023[1]

+50% increase in R&D expenditure since 2018[1]

90% of clinical drug development fails[2]

Costly trial and error: Only one out of 10,000 new drug candidates reaches the market

Research → Commercial production



>€2bn

1 out of 10,000

> of 10 years

1 IQVIA 2024 2 Why 90% of clinical drug development fails and how to improve it? – ScienceDirect

Enabling scientists in the lab to accelerate and improve workflows; contributes to reducing time and cost of drug development

Solutions are used to

- Conduct experiments
- Make better use of data
- Understand diseases
- Identify molecules
- Develop new drugs

BioAnalytics

Instruments, consumables, and reagents for drug discovery & development and life science research

~1/3
of sales revenue
Over-proportionate profitability

Lab Essentials

Instruments and consumables for quality-critical work steps in laboratories

~2/3
of sales revenue

FY 2024 figures

SARTORIUS

BioAnalytics digitizes and automizes key research steps in biopharma labs

- Highly automated to reduce manual efforts
- Valuable data to make better decisions earlier in the process
- Leveraging technologies like AI, machine learning, and data analytics
- Decreasing likelihood of late-stage failure, shortening time-to-clinic

Real-time, live-cell imaging & analysis

Incucyte

Boosting productivity via parallel experiments with **6x more** capacity than traditional approaches

Rapid picking and screening of clones

CellCelector

Integrating clone selection workflow **saves 5+ weeks**, compared to traditional method

Label-free characterization in real-time

Octet

Reduces titer and CQA screening time during cell line development by up to **99%** vs. traditional methods

High content, high throughput screening

iQue

Provides actionable results for large scale antibody screening experiments **3-9x faster** than competition

BioAnalytics portfolio increasingly synergetic with BPS products

Application example: cell line development	Gene cloning, initial selection	Clone selection, analytics	Cultivation, media optimization	Evaluation, characterization	Cell banking
LPS (BioA) instruments 	■	■	■	■	
BPS instruments 			■	■	■
Reagents, consumables and software					

Lab Essentials for quality-critical steps and applications in the lab

Main product groups

Lab balances | Lab filtration | Liquid handling | Microbial QC | Lab water

- Positioned as premium-provider and innovator
- ~10% market share
- Growth potential especially in the U.S. and Asia
- High gross margins offer potential for scale effects
- Opportunity to cross-sell BioAnalytics portfolio

Lab market expected to grow low- to mid-single digit

- Pharma and biopharma the largest customer group; rising number and complexity of drugs in development as main demand driver
- Battery, electronics, food & beverage also fast growing R&D segments in industrial markets
- Growth driven by R&D spending in the individual end markets
- Academic and public-sector research institutions benefiting from budget increases
- Increasing regulatory requirements in all regions and markets

Substantial share of recurring business

Instrument sales followed by recurring revenue stream

Software + Consumables + Reagents + Service

Further increasing recurring share

~50%

Recurring revenue

SARTORIUS

Innovation strategy is focused on key workflows addressing unmet needs of customers

Expand portfolio

Complementary solutions, focus on innovation in key areas

Focus areas

Advanced cell models	New modalities	Data management & analytics
Provide tools for generation and analysis of 3D cells models predictive of drug efficacy	Reliable, real-time analytical characterization & QC solutions	Connected devices & enhanced AI-driven analytics

Agenda

Overview | Strategy

Bioprocess Solutions Division (BPS)

Lab Products & Services Division (LPS)

H1 2025 Results | FY 2025 Guidance

Robust sales revenue growth and substantial increase in profitability

Sartorius Group in millions of € unless otherwise specified	H1 2024	H1 2025	▲ in %	▲ in % cc[1]
Sales revenue	1,680	1,767	+5.2	+6.1
Underlying EBITDA[2]	471	527	+11.9	
Underlying EBITDA[2] margin in %	28.1	29.8	+1.7pp	
Underlying EPS[3] (ord.) in €	2.15	2.44	+13.5	
Underlying EPS[3] (pref.) in €	2.16	2.45	+13.4	

- Growth driven by double-digit increase in recurring business in all regions; equipment and instruments business still soft
- Reciprocal US tariffs with negligible impact on sales revenue and margin in H1
- Rolling 12-month B-t-B ratio above 1; consistently improving
- Significant margin expansion driven by volume, product mix and economies of scale

1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate

Solid growth momentum across all regions

EMEA
Sales | € in millions



Americas
Sales | € in millions



Asia | Pacific
Sales | € in millions



Sales by region
in %



- Consumables business growing in all regions while equipment and instruments business still soft

Acc. to customers' location; growth in constant currencies

Bioprocess Solutions: Significant growth and margin expansion

Sales revenue
€ in millions



UI EBITDA & margin
€ in millions



- Strong recurring business with consumables more than compensates for industry-wide soft equipment business
- Overproportionate increase in underlying EBITDA driven by volume, product mix and economies of scale

Lab Products & Services: Soft end markets weigh on performance

Sales revenue
€ in millions



UI EBITDA & margin
€ in millions



- Instruments business impacted by muted investment activity of customers, particularly in bioanalytical instruments
- Solid growth of recurring business with lab consumables and services in all regions
- Underlying EBITDA margin down on softer volumes and product mix

Substantial increase in net profit and solid free cash flow generation

Sartorius Group in millions of € unless otherwise specified	H1 2024	H1 2025	in %
Underlying net profit[1,2]	148	**169**	+13.7
Reported net profit[2]	61	**81**	+33.0
Operating cash flow	347	**289**	-16.6
Free cash flow	108	**122**	+13.0
Capex ratio (in %)	13.6	**9.1**	-4.5pp

- Operating cash flow on solid level; growth-driven increase in working capital to maintain delivery capability
- Free cash flow up due to lower capex in H1; capex spend in 2025 back-end loaded

1 Underlying net profit = net profit adjusted for extraordinary items, amortization and based on a normalized financial result and a normalized tax rate   2 After non-controlling interest

Deleveraging on track; commitment to investment-grade rating

Key financial indicators

Sartorius Group in millions of € unless otherwise specified	Dec. 31, 2024	Jun. 30, 2025
Equity ratio in %	38.6	**37.8**
Net debt	3,746	**3,836**
Net debt | underlying EBITDA	4.0	**3.8**

Net debt and net debt to underlying EBITDA



Strong credit metrics and liquidity

Investment grade credit rating BBB- (stable)

- Commitment to maintain a solid investment grade rating
- Focus on cash generation and continued deleveraging

Strong liquidity & resilient financing

- Cash position of >€800m
- €800m undrawn syndicated credit facility, maturing in 2029
- No financial covenants, 100% senior unsecured
- All debt financing at fixed interest rates; limited sensitivity to interest rate changes

Balanced debt maturity profile



All figures as of December 31, 2024

2025 guidance confirmed

Guidance 2025	Sartorius Group	Bioprocess Solutions	Lab Products & Services
Sales revenue growth[1]	+ ~6% (+/- 2pp)	+ ~7% (+/- 2pp)	+ ~1% (+/- 2pp)
Underlying EBITDA margin	~29% to ~30%	~31% to ~32%	~22% to ~23%

- Capex ratio of around 12.5%
- Net debt/underlying EBITDA to decrease to approx. 3.5 at year-end
- MatTek acquisition to add a good 1pp to LPS FY revenue development; margin effect negligible

For financial modelling on Group level

Depreciation	260mn to 270mn €
Normalized financial result	-165mn to -175mn €
Normalized tax rate	~27%

Disclaimer: The sales and margin forecast does not include possible effects of tariffs and related mitigating or corrective measures, which, depending on their design, scope and duration, could impact sales and margin development temporarily to a certain extent. Management does not expect any influence on the strong position and competitiveness of Sartorius.

1 Organic, in constant currencies

Appendix

Corporate responsibility & further financial information

To Sartorius, sustainability means operating responsibly over the long term – with respect to business partners, employees and society as well as to natural resources. Learn more about our commitment:

SRI Presentation



Please click below for further information:

Financial Publications

Earnings Release H1 2025

Annual Report 2024

Investor Relations Website

Sartorius AG

Sartorius Stedim Biotech S.A.

Reasons to invest

- Clear strategy, consistent implementation
- Strong fundamental growth drivers
- Competitive, differentiated product portfolio
- High share of recurring revenues
- High-performance, resilient production and R&D infrastructure
- Ambitious team, strong customer focus

Sartorius legal & operational structure

Sartorius Group legal setup

Sartorius AG (~69.0m shares)
Stock market listed in Germany[1]

Ordinary shares (~34.2m shares)
~55% Administered by executor
~38% Bio-Rad Laboratories
~7% Free float

Preference shares (~34.8m shares)
~72% Free float
~28% Bio-Rad Laboratories

~71.5%

100%

Sartorius Stedim Biotech S.A.
Stock market listed in France

97.3m shares
~71.5% Sartorius AG
~28.5% Free float

Other Sartorius subsidiaries

Bioprocess Solutions division

Lab Products & Services division

Sartorius Group operational setup

1 The ownership relates to outstanding shares and thus excludes treasury shares. Information on shareholdings and shares in free float pursuant to the disclosure requirements of Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders' own disclosures. The legal disclosure requirements refer only to voting shares and not to non-voting preference shares.

Share price performance



ISIN	DE0007165631 (preference share) DE0007165607 (ordinary share)
Ticker	SRT3 (preference share) | SRT (ordinary share)
Number of shares	69,035,489 - thereof pref. shares: 34,807,268 (excluding ~2.6m treasury shares); ord. shares: 34,230,928 (excluding ~3.2m treasury shares)
Indices	DAX 50 ESG | MDAX | TecDAX | MSCI Europe CDAX | Prime All Share Index | Technology All Share Index | STOXX Europe 600
Market cap.	€13.8bn (as of July 21, 2025)

A sampling of the Bioprocess Solutions' product portfolio

Filtration

Purification

Fermentation

Fluid management

A sampling of the Lab Products and Services’ product portfolio

Lab balances | Lab water systems

Bioanalytics

Lab filtration | Microb. analysis

Pipettes

Executive Board of Sartorius AG as of July 1, 2025

Michael Grosse, CEO

Joined Sartorius in 2025
Member of the Board since
July 1, 2025

Group Strategy, Corp. Research, HR, Legal, Communications, Sustainability

René Fáber

Joined Sartorius in 2002
Member of the Board since 2019

Bioprocess Solutions Division

Florian Funck, CFO

Joined Sartorius in 2024
Member of the Board since 2024

Finance, IT & Processes, Corporate Sourcing, Compliance, Internal Audit

Alexandra Gatzemeyer

Joined Sartorius in 2005
Member of the Board since 2023

Lab Products & Services Division

Contacts and Financial calendar

Petra Müller

Head of Investor Relations

+49.551.308.6035
petra.mueller2@sartorius.com

Mirko Koch

Manager Investor Relations

+49.551.308.2402
mirko.koch@sartorius.com

Sartorius Corporate Administration GmbH
Otto-Brenner-Straße 20
37079 Göttingen, Germany

- **October 16, 2025**
  Publication Q3 | 2025 Results
- **November 12, 2025**
  Stifel 2025 Healthcare Conference, New York
- **November 18, 2025**
  Jefferies London Healthcare Conference, London

Disclaimer

This presentation contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize.
This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.

Simplifying Progress

Scan or click here to view this presentation.